ProCE Banner Activity

BOVen: Phase II Trial of Zanubrutinib, Obinutuzmab, and Venetoclax in Treatment-Naive TP53-Mutated Mantle Cell Lymphoma

Conference Coverage

In the phase II BOVen trial, first-line combination therapy with zanubrutinib, obinutuzmab, and venetoclax achieved a 2-year PFS of 72%, with manageable safety, in patients with high-risk TP53-mutated mantle cell lymphoma.

Released: December 14, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.